“`html
Alvotech (ALVO) shares rose 8.6% to close at $8.7 on the last trading session, following a two-day rally initiated by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backing its regulatory filings for biosimilar versions of Amgen’s Prolia/Xgeva and Johnson & Johnson’s Simponi. This upswing comes after ALVO experienced a 3.7% loss over the prior four weeks.
For the upcoming quarterly earnings report, Alvotech is expected to report earnings of $0.08 per share, reflecting a year-over-year decline of 57.9%, along with projected revenues of $114.27 million, marking an 11% increase from the previous year. The consensus EPS estimate has remained unchanged over the past 30 days.
In the same industry, Cytek Biosciences (CTKB) closed the last trading session down 3.9% at $3.71, with an unchanged EPS estimate of $0.01 for the upcoming report, indicating no change from the previous year.
“`
